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ABSTRACT
Background: Rubella, syphilis, toxoplasmosis, cytomegalovirus (CMV), hepatitis B (HBV) and C
(HCV), HIV, and Group B Streptococcus (GBS) infections may have very severe outcomes during
pregnancy, and for this reason, monitoring of infections in pregnant women is a requirement of
prenatal assistance.
Aims: To describe coverage and outcome of the screening for rubella, syphilis, toxoplasmosis,
CMV, HBV, HCV, HIV, and Group B Streptococcus in pregnancy in the Autonomous Province of
Trento, Northern Italy (538,600 inhabitants).
Methods: We analysed the coverage and outcome of the above-mentioned screenings among
women who delivered in the hospitals of the Province of Trento between 2007 and 2014
(N¼ 38,712). Screenings were grouped according to characteristics such as recommendation by
national and local guidelines, scheduling of the tests, operating methods, and charge. We also
estimated odds ratios (ORs) for missing screening for selected infections through multiple logistic
regression.
Results: Estimated uptake of antenatal screening was 99.7% for rubella, 99.3% for syphilis, 99.7%
for toxoplasmosis, 98.1% for HIV infection, 99.0% for HBV, 98.9% for HCV, 94.0% for GBS infec-
tion, and 75.4% for CMV infection. The overall prevalence of immunity was 94.1% for rubella,
24.2% for toxoplasmosis, and 64.2% for CMV. The rate of seroconversion in pregnant women
was 0.02% for rubella, 0.29% for toxoplasmosis, and 0.75% for CMV. The overall prevalence of
infection was 0.94% for HBV, 0.53% for HCV, 22.3% for GBS, 0.29% for syphilis, and 0.13% for
HIV. We found a significant positive association for all screening tests, between lack of testing
and late first medical examination in pregnancy (ORs ranging from 1.20 to 1.66 for the first med-
ical visit in the second trimester and ORs ranging from 1.60 to 5.88 for the first medical visit in
third trimester, compared to early medical visit in the first trimester). Compared to Italian citizen-
ship, foreign citizenship of the mother was also positively associated with absence of screening
(ORs ranging from 1.30 to 1.53). A significant inverse association was observed for calendar year
of delivery (ORs ranging from 0.71 to 0.97, for 1 year increment). Less educated mothers and
pluriparae were also at higher risks of not being tested. Analysis of the association with mother
age showed different heterogeneous effects.
Conclusions: Our study indicates that the attention to screening and detecting infected cases is
growing over the time. In addition, care delivered during pregnancy has a leading role in deter-
mining coverage of the examinations. Immigrant, pluriparous and less educated women need
particular attention.
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Introduction
Rubella, syphilis, toxoplasmosis, cytomegalovirus
(CMV), hepatitis B (HBV) and C (HCV), HIV, and Group
B Streptococcus (GBS) infections may have very severe
outcomes if contracted during pregnancy, and moni-
toring of infections in pregnant women is a fundamen-
tal requirement of prenatal assistance.
Prevention has the leading role in defeating prenatal
infections, but early diagnosis is also crucial. Early detec-
tion of infected mothers allows timely intervention, first
to reduce the risk of vertical transmission and second to
treat for any damage that may result in the newborn.
We address here the coverage of selected investiga-
tions and their outcome in women who delivered in
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the Autonomous Province of Trento (with a population
of 538,600 people in the North-East Italy) in the years
2007–2014. The Autonomous Province of Trento,
through the Local Health Trust (Azienda Provinciale
per i Servizi Sanitari – APSS, Servizio Epidemiologia
clinica e valutativa), provided the update of its CedAP
(Certificato di Assistenza al Parto, 1996) informative
service, including additional information related to
investigations for infections carried out by women dur-
ing pregnancy, which are therefore systematically col-
lected on all deliveries taking place in the Province.
Materials and methods
Study population
Out of a total of 39,787 deliveries registered in CedAP
between 2007 and 2014, we excluded cases of birth in
extraregional structures, home or rushing deliveries, and
women who wanted to keep anonymity at birth (1039
women in total). In addition, 36 cases without registra-
tion of information on investigations were also excluded.
The final population is thus composed of 38,712
women who had given birth in all the provincial hos-
pitals (N¼ 7) in the years 2007–2014.
Investigations groups
The infections were studied by dividing them into four
groups, distinct for diversity and testing timing.
1. Toxoplasmosis, rubella, syphilis, and HIV infections.
National and local guidelines for prenatal care rec-
ommend the screening for these infections at the
beginning of pregnancy, at the first visit during
pregnancy, possibly within the 12-gestational
week. All these examinations are free of charge
according to Italian law. The tests for Rubella,
Toxoplasmosis, HIV infection, and Syphilis evaluate
the presence of specific antibodies.
2. HBV and HCV. National guidelines recommend
screening for HBV in the third trimester, while
screening for HCV should be proposed only to
women with related risk factors. Local guidelines
actually propose both those screenings in the
third trimester. The aforementioned screenings are
included among those free of charge between 33
and 37 gestational weeks. The HCV test evaluates
the presence of specific antibodies while the HBV
test assess the HBsAg antigen.
3. GBS examination. National and local guidelines
recommend to perform this test between 36–37
gestational weeks. This test is not free of charge
according to Italian law. Given the timing of the
examination, it is sometimes performed at the
birth point chosen for delivery. For this reason,
the performance of this examination depends
even on logistic and organizational aspects of the
care setting. Research for GBS is performed
through vaginal and rectal swab.
4. CMV screening is the only one not routinely rec-
ommended in pregnancy either by national or
local guidelines. Local guidelines promote it in
selected cases since the first visit (12–13 gestational
weeks). CMV testing is also not free of charge. The
CMV test evaluates specific antibodies.
Statistical analysis
We estimated the relative risks (RRs) of not getting
tested for all the infections of each group, through the
odds ratios (ORs) and related 95% confidence intervals
(CIs). We fitted a multiple logistic regression model
including terms for calendar year of delivery, time of
the first visit in pregnancy, citizenship, age class, par-
ity, and education level of the women.
Results
Table 1 shows the demographic characteristics of
women who delivered in the Autonomous Province of
Trento over the years considered. Women were mainly
Italian, resident in the Province, aged between 15 and
53 years with a median of 32 years and with a high
school degree and a bachelor/master degree.
CedAP data show strong adherence to screening
for infectious diseases during pregnancy
(Supplementary Table 1). Rubella, HIV infection, toxo-
plasmosis, Syphilis: the coverage rate for each one is
over 97% each year, with an increase over the years.
The percentage of women who got tested for all these
infections was 97.2% over the 8 years of observation.
As regards rubella, most of the women who had
been tested were found immune (94.1%) and the pro-
portion remained similar throughout the years.
Approximately 5–6% of women were susceptible, with
seven cases of seroconversion in pregnancy, respect-
ively, in 2007 (one case), 2008 (three cases), 2013 (one
case), and 2014 (two cases).
Women who were not immune to toxoplasmosis
were 75.5% of the women tested (99.7%, 38,575
women) and 24.2% were immune. Over time, there
was a decrease in the proportion of immune cases in
favour of an increase in nonimmune ones. Women
who had a seroconversion in pregnancy were 110,
with a range of 10–18 cases per year.
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Syphilis test was performed on 99.3% of women:
positive cases were between 8 and 19 per year, for a
total of 112 cases. HIV test was performed on 98.1% of
women. Among these, cases of HIV positivity were 49
(range of 4–9 cases per year).
HBV and HCV: the coverage for HBV and HCV inves-
tigations increased from about 97% in 2007 to over
99% in 2014. During the 8 years, 98.7% of the women
had been tested for both diseases during pregnancy.
Most of the women were negative for HBV or vacci-
nated (98.8 and 0.3%, respectively). The total number
of cases of HBV positivity was 362 with a slight
increase over the years: from a minimum of 37 cases
per year (2009) to a maximum of 54 cases per year
(2014). Positivity cases for HCV were in total 203, with
a range of 19–36 cases per year.
GBS screening shows a 94% adherence over the 8
years. The proportion of women positive to GBS was
22.3% (8117 women) of the screened ones with a
range of 914 (2014) to 1106 (2012) annual cases.
In total, 75.4% of women got tested for CMV.
However, the proportion of screening among women
increased significantly over the years, from 59.6% in
2007 to 95.6% in 2014. Women with prepregnancy
infection were 64.2% in the considered years while the
CMV-negative case were 35.1%. Women who had
reinfection/reactivation in pregnancy were 97, from a
minimum of three cases per year (2008) to a maximum
of 33 (2013). New infections registered in pregnancy
were 123, with a range of 5–24 cases per year.
Table 2 shows the ORs, and corresponding 95%CIs,
for not being tested in relation to groups of infections
by demographic characteristics of the woman and
some features related to the health care assistance.
Foreign women had a higher risk (OR: 1.37, 95%CI:
1.18–1.59) than Italian of not being tested for either
Rubella, HIV, Toxoplasmosis, and Syphilis. First preg-
nancy (OR: 0.63, 95%CI: 0.55–0.72) was inversely
related to the risk of not getting tested compared to
subsequent pregnancies. The two middle age classes
also exhibited lower risk (OR: 0.73, 95%CI: 0.60–0.88
for women between 26 and 30 years and OR: 0.71,
95%CI: 0.58–0.86 for women between 31 and 35 years)
compared to women aged 25. Delay of the first
medical examination in pregnancy significantly
increased the risk of not being tested: compared to
women who attended the first visit in the first trimes-
ter, those who made it in the second trimester had an
OR of 1.66 (95%CI: 1.41–1.97) and visit in third trimes-
ter is associated to an OR of 5.88 (95%CI: 4.54–7.60).
The year of birth was inversely associated with the
lack of testing (1 year increase implies a 14% lower
OR, 95%CI of OR: 0.83–0.88).
Foreign citizenship (OR: 1.30, 95%CI: 1.04–1.62)
increased the risk of not being screened for both HBV
and HCV compared to Italian women. First-parity (OR
of 0.80, 95%CI: 0.66–0.97) was inversely associated
with the risk of not taking the examinations compared
to subsequent pregnancies. Late first check (OR for
third trimester visit: 2.04, 95%CI: 1.24–3.37) was associ-
ated to a higher risk with respect to early check.
Giving birth in recent years (OR for 1 year increase:
0.76, 95%CI of OR: 0.73–0.80) was inversely associated
with the risk of not taking both tests.
Regarding to GBS screening, foreign citizens (OR:
1.51, 95%CI: 1.36–1.67) exhibit a higher risk of not get-
ting tested with respect to Italian women. Lower aca-
demic qualification (OR: 1.17, 95%CI: 1.05–1.31 for high
school graduates and OR: 1.42, 95%CI: 1.25–1.62 for
women with even lower education level compared to
highest degrees), older age (OR: 1.25, 95%CI: 1.07–1.45
for women between 36 and 40 and OR: 1.53, 95%CI:
1.23–1.91 for women over 40 years compared to
women aged 25) and the timing of first visit (OR for
first visit in the second trimester: 1.35, 95%CI:
1.19–1.53, OR for first visit in the third trimester: 2.12,
Table 1. Distribution of the study population (N¼ 38,712)
according to selected characteristics in Italy, 2007–2014.
n %
Age group (years)
<26 5440 14.05
26–30 10,348 26.73
31–35 13,373 34.54
36–40 7946 20.53
>40 1605 4.15
Citizenship
Italian 29,475 76.14
European 5265 13.60
Extra-European 3972 10.26
Residence
Italy (province of Trento) 36,814 95.10
Italy (extra-province) 1294 3.34
Abroad 604 1.56
First check in pregnancy timing
1 trimester 32,789 84.70
2 trimester 5412 13.98
3 trimester 511 1.32
Education level
University 10,545 27.24
High school 20,709 53.50
Medium high school 6568 16.97
Licenza elementary/none 890 2.30
Parity
Primiparous 18,324 47.33
Pluriparous 20,388 52.67
Year of delivery
2007 4862 12.56
2008 5070 13.10
2009 4967 12.83
2010 5018 12.96
2011 4905 12.67
2012 4804 12.41
2013 4592 11.86
2014 4494 11.61
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95% CI: 1.64–2.75 compared to early check) were asso-
ciated to a higher risk of not getting tested.
Factors positively associated to the risk of not being
tested for CMV infection were foreign citizenship (OR:
1.53, 95%CI: 1.44–1.63), lower educational level (OR:
1.32, 95%CI: 1.24–1.40 for high school graduates and
OR: 1.65, 95%CI: 1.53–1.78, for women with an even
lower degree with respect to higher degrees) and the
timing of the first visit (OR for visit in the second tri-
mester: 1.30, 95%CI: 1.20–1.40 and OR for first visit in
the third trimester: 1.60 95%CI: 1.32–1.40 compared to
early first check). Delivering in recent years is a pro-
tective factor: 1 year increase had an OR of 0.71
(95%CI: 0.71–0.72) of not getting tested.
Discussion
This analysis shows a high rate of coverage for all tests
in the Province of Trento, and the rate of coverage for
nonrecommended/nonfree of charge tests is also
increasing over time. For all types of tests, there is a
strong influence of the care setting in determining the
coverage of the investigations. In addition to the year
of delivery, the time of the first medical visit in preg-
nancy is an important predictor of whether or not a
woman will get the test. For each of the four groups of
infections, which refer to tests to be made at different
moment of pregnancy, women who undergo their first
check in the second or third trimester are penalized,
even for tests to be performed in the third trimester
such as hepatitis or towards the end of pregnancy such
as GBS. Further, low education and foreign citizenship
were associated with an increased risk of not being
screened for most of infections. Ethnic or economic dis-
advantage has been reported associated with lower
screening rates also in other populations [1]. These
results are in general agreement (or possibly showing
higher rates of coverage) with data from other popula-
tions. The European Centre for Disease Prevention and
Control delivered a survey on antenatal screening for
HIV, HBV, syphilis and rubella. Twenty-six EU/EEA coun-
tries participated in the survey. Testing coverage was
over 95% in 12 out of the 18 European countries for
HIV, in eight out of the 13 countries for HBV, in 14 out
of the 18 countries for syphilis and in four countries
out of the five countries for rubella [2]. In an analysis of
a large administrative database in USA including 98,709
Medicaid-insured pregnant women, 96.3% were
screened for syphilis, 96.3% for HBV, 82.4% for HIV [3].
Another interesting finding of this analysis is the
opportunity of analyse the frequency of infections in
pregnancy. Our findings are generally in agreement
with available data from Italy or other populations.
Studies on Rubella infection in Italy reported rates
of sero-prevalence among women of childbearing age
and pregnant women in Italy about 90%, with higher
Table 2. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for lack of testing in pregnancy according to
selected covariatesa.
Toxoplasmosis & Syphilis &
Rubella & HIV infection HBV & HCV infection GBS infection CMV infection
N (%) OR (95%CI) N (%) OR (95%CI) N (%) OR (95%CI) N (%) OR (95%CI)
Citizenship
Italianb 688 (2.33) 1 335 (1.14) 1 1536 (5.21) 1 6561 (22.26) 1
Foreign 399 (4.32) 1.37 (1.18–1.59) 160 (1.73) 1.3 (1.04–1.62) 777 (8.41) 1.51 (1.36–1.67) 2977 (32.23) 1.53 (1.44–1.63)
Education level
Universityb 253 (2.40) 1 101 (0.96) 1 505 (4.79) 1 1865 (17.69) 1
High school 503 (2.43) 0.86 (0.74–1.01) 253 (1.22) 1.08 (0.85–1.36) 1196 (5.78) 1.17 (1.05–1.31) 5171 (24.97) 1.32 (1.24–1.40)
Lower 331 (4.44) 1.14 (0.95–1.37) 141 (1.89) 1.35 (1.02–1.78) 612 (8.21) 1.42 (1.25–1.62) 2502 (33.55) 1.65 (1.53–1.78)
Parity
Primiparous 396 (2.16) 0.63 (0.55–0.72) 210 (1.15) 0.80 (0.66–0.97) 953 (5.20) 0.85 (0.77–0.93) 4347 (23.72) 0.89 (0.85–0.94)
Pluriparousb 691 (3.39) 1 285 (1.40) 1 1360 (6.67) 1 5191 (25.46) 1
Age group (years)
25b 224 (4.12) 1 99 (1.82) 1 371 (6.82) 1 1706 (31.36) 1
26–30 263 (2.54) 0.73 (0.60–0.88) 129 (1.25) 0.78 (0.59–1.03) 559 (5.40) 0.95 (0.82–1.09) 2685 (25.95) 1.31 (1.13–1.51)
31–35 325 (2.43) 0.71 (0.58–0.86) 153 (1.14) 0.72 (0.54–0.96) 737 (5.51) 1.04 (0.90–1.19) 3117 (23.31) 1.21 (1.06–1.39)
36–40 227 (2.86) 0.83 (0.67–1.02) 99 (1.25) 0.81 (0.59–1.12) 518 (6.52) 1.25 (1.07–1.45) 1698 (21.37) 1.08 (0.95–1.24)
>40 48 (2.99) 0.85 (0.61–1.19) 15 (0.93) 0.62 (0.35–1.09) 128 (7.98) 1.53 (1.23–1.91) 332 (20.69) 1.02 (0.89–1.17)
First check upc
1 trimesterb 805 (2.36) 1 405 (1.19) 1 1886 (5.54) 1 7977 (23.41) 1
2 trimester 195 (4.72) 1.66 (1.41–1.97) 72 (1.74) 1.20 (0.92–1.56) 354 (8.57) 1.35 (1.19–1.53) 1347 (32.62) 1.30 (1.20–1.40)
3 trimester 87 (17.03) 5.88 (4.54–7.6) 18 (3.52) 2.04 (1.24–3.37) 73 (14.29) 2.12 (1.64–2.75) 214 (41.88) 1.60 (1.32–1.94)
Year of delivery
1 year increment 0.86 (0.83–0.88) 0.76 (0.73–0.80) 0.97 (0.95–0.99) 0.71 (0.71–0.72)
aORs and 95%CIs derived from multiple logistic models, one for each screening group, including all variables listed.
bReference category.
cThe variable was categorized as following: 1 trimester (up to 13 gestational weeks), 2 trimester (from 13þ 1 gestational weeks to 27 gestational
weeks), 3 trimester (from 27þ 1 gestational weeks on).
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values in the North than in the South [4–9]. At the
international level, 27 EU/EEA countries reported
38,847 cases of rubella, with 12.6% cases in females
[2]. Most of them derived from a large rubella out-
break which occurred in Poland [10]. In Romania, 119
rubella cases in pregnant women were reported in
2013, after an outbreak in 2011–2012 [11].
The prevalence of syphilis infection was comparable
to that reported in the Italian literature, which ranges
from 0.22 to 0.49% in various Italian regions [12–15].
The rate of registered syphilis among woman in EU/
EEA countries was 1.6 per 100,000 in 2013, with a min-
imum in Croatia/Slovenia (0.3) and a maximum in
Lituania (7.7) [2].
The frequency of toxoplasmosis infection in preg-
nancy was also comparable with the Italian literature,
which reported ranges between 0.09 and 4.8%
[13,16,17]. The reported rate of toxoplasmosis infection
in pregnancy varied in different European countries
from 0.17 to 0.24% with maternal-fetal transmission in
23–44% of cases not treated [17–21].
Studies on HIV infection in pregnancy in Italy show
slightly lower values than those found in this study,
with a maximum of 0.09% [13,22]. From 2000 to 2004,
HIV infection in pregnant women was below 0.1% in
16 European countries. The highest values were
reported for Estonia and Ireland (over 0.3%), and
between 0.1 and 0.2% in Latvia, Romania, Spain, and
the UK [2,23].
Results for HBV and HCV are also comparable with
other Italian datasets reporting ranges, respectively,
from 0.79 to 1.7% (HBV) and between 0.4 and 2.4%
(HCV) [13,24–27]. The reported HBV prevalence among
pregnant women ranges between 0.14% (Finland) and
1.15% (Greece) [28]. Limited data on HCV in pregnant
women in Europe are available [29]. A study in the
Netherlands reported a seroprevalence of 0.33% in
2003 [30], while in a Russian study it was 3% [31].
CMV infection estimate in Italy varies between 0.28
and 0.9% [13,32] with a range comparable with our
result. Reported rates of CMV primary infection in
pregnancy in the word range from 0.5 to 4% [33,34],
and the incidence of seroconversion among pregnant
women ranges from 0.4 to 2% [32,35–38] depending
on the prevalence of infection in the populations.
The frequency of GBS infections was also similar to
those reported by literature, although higher with
respect to Italian studies, ranging from 7.98 to 13.6%
[13,39]. Limited data are available on GBS infection in
pregnancy in Europe: in most countries, the preva-
lence of infection range between 10 and 20%, and the
incidence of neonatal disease ranges from 0.5 to 2.0
per 1000 live births [40,41].
In summary, this work has allowed to see how the
welfare setting has a strong influence on the coverage
of the surveys, sometimes showing more importance
than the individual characteristics of women that
showed somewhat stronger effects in relation to tests
which are less promoted/recommended in the prenatal
assistance. An additional interest in our study was to
provide data on adherence to investigations in relation
to demographic characteristics of women. There are, in
fact, aspects that are beyond the connotations of the
setting of assistance and the characteristics of the
screenings and outline specific groups of women who
need greater attention. Among them, non-Italian citi-
zens, pluriparous and less educated mothers are at risk
for not uptaking pregnancy screening. These findings
may be useful to focus specific preventive campaigns.
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